[Initial antithrombotic therapy for pulmonary embolism].

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Context:

• Pulmonary embolism (PE) management for hemodynamically stable patients begins with antithrombotic therapy.
• Current treatment involves a two-phase approach: initial parenteral anticoagulation followed by oral vitamin K antagonists.
• Existing therapies, while effective, present challenges such as parenteral administration and the necessity for monitoring.

Purpose:

• To outline the current therapeutic strategies for pulmonary embolism.
• To discuss the limitations of existing anticoagulant treatments.
• To anticipate the role of novel anticoagulants in PE management.

Summary:

• Initial treatment for stable pulmonary embolism relies on antithrombotic agents to prevent thrombus progression and recurrence.
• Standard therapy includes parenteral anticoagulants (heparin, low molecular weight heparins, fondaparinux) followed by vitamin K antagonists.
• Low molecular weight heparins and fondaparinux are preferred in French guidelines, but unfractionated heparin is crucial in specific scenarios like renal impairment or high bleeding risk.

Impact:

• Highlights the ongoing evolution of anticoagulant therapy for pulmonary embolism.
• Suggests that next-generation anticoagulants are poised to become the standard of care for most PE patients.
• Emphasizes the continued relevance of traditional anticoagulants in select clinical situations.